NCT00783744 - Insulin Glargine Combination Therapies in Type II Diabetics | Biotech Hunter

Enrollment

375

Participants

Timeline

Start Date

December 31, 2001

Primary Completion Date

August 31, 2003

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Insulin Glargine

In the morning to target FBG ≤ 100 mg/dl

DRUG

Glimepiride

Glimepiride 3 or 4 mg

DRUG

Metformin

At least 850 mg od

DRUG

Insulin monotherapy with premixed insulin NPH 30/70

Given before breakfast and before dinner, target of pre-prandial BG ≤ 100 mg/dl

Trial Locations (10)

Sanofi aventis administrative office, Vienna

Sanofi-aventis administrative office, Helsinki

Sanofi-aventis administrative office, Paris

Sanofi-Aventis Administrative Office, Berlin

Sanofi-Aventis Administrative Office, Milan

Sanofi-Aventis Administrative Office, Gouda

Sanofi-Aventis Administrative Office, Barcelona

Sanofi-Aventis Administrative Office, Bromma

Sanofi-Aventis Administrative Office, Geneva

Sanofi-Aventis Administrative Office, Guildford